Superworth

CareDx free cash flow CDNA

Cash from operations less capital spending, by quarter and over the last twelve months, from 2013.

Last 12 months, to Jun 30, 2026
n/m
a quarter missing
Latest quarter, Q2 FY26
$28.7M
+223% on a year earlier
Fiscal year 2018
−$6M

CareDx's twelve-month free cash flow can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was $28.7M, up 223% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2018−$6Mn/a
FY2017−$14.5Mn/a
FY2016−$17.1Mn/a
FY2015−$11Mn/a
FY2014−$4.1Mn/a
FY2013n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26$28.7M+223%n/a
Q1 FY26$514Kn/an/a
Q2 FY25$8.9Mn/an/a
Q1 FY25−$28.2Mn/an/a
Q3 FY21−$3.2M−264%n/a
Q2 FY21$7M−69%n/a
Q1 FY21−$34.9Mn/an/a
Q3 FY20$2M+906%n/a
Q2 FY20$22.4M+529%n/a
Q1 FY20−$4.8Mn/an/a
Q3 FY19$196Kn/a−$1.6M
Q2 FY19$3.6Mn/a−$2M

Against its peers

Companies in Medical - Diagnostics & Research nearest CareDx's size, closest first, today.

CompanyFree cash flow yield
CDNACareDxn/m
VCYTVeracyte4.3%
BLLNBillionToOne0.7%
LNTHLantheus6.0%
CAICaris Life Sciences1.4%
BIOBio-Rad Laboratories3.6%
RVTYRevvity3.2%
MEDPMedpace3.8%
NRCNRC Health4.5%
LHLabcorp4.3%
DGXQuest Diagnostics5.1%
Peer median4.0%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on CareDx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.